{
    "clinical_study": {
        "@rank": "75532", 
        "acronym": "EASE-PRM-PCI", 
        "arm_group": [
            {
                "arm_group_label": "n-acetyl cysteine", 
                "arm_group_type": "Experimental", 
                "description": "30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure"
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and\n      cerebral events in patients undergoing primary percutaneous coronary intervention who have\n      moderate to high risk for contrast induced nephropathy.\n\n      In a sub-group of patients coronary flow reserve will be evaluated."
        }, 
        "brief_title": "Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention", 
        "condition": "Acute ST Segment Elevation Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Acute ST Elevation Myocardial Infarction undergoing Primary\n             Percutaneous Coronary intervention Who Have Moderate to High Risk For Contrast\n             Induced Nephropathy (Mehran Score \u22655)\n\n        Exclusion Criteria:\n\n          -  Patients <18 years old with moderate to high risk for contrast induced nephropathy\n             undergoing percutaneous coronary intervention\n\n          -  Low risk for contrast induced nephropathy (Mehran Score <5)\n\n          -  Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)\n\n          -  Infection\n\n          -  Pregnancy, Lactation\n\n          -  Renal failure requiring dialysis\n\n          -  Hepatic failure\n\n          -  Allergy to NAC\n\n          -  History of Asthma\n\n          -  Chronic nitrate usage\n\n          -  Malignancy\n\n          -  Use of corticosteroids\n\n          -  Leucocytosis,Thrombocytosis,Anemia\n\n          -  Blood pressure of >180/100mmHg despite anti-hypertensive therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878344", 
            "org_study_id": "ozaydin290"
        }, 
        "intervention": [
            {
                "arm_group_label": "n-acetyl cysteine", 
                "intervention_name": "NAC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "intervention_name": "Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "contact": {
                "email": "aydoganer@hotmail.com", 
                "last_name": "Dogan Erdogan, MD", 
                "phone": "+0902462324479", 
                "phone_ext": "1140"
            }, 
            "facility": {
                "address": {
                    "city": "Isparta", 
                    "country": "Turkey", 
                    "state": "Mediterranean Region", 
                    "zip": "32260"
                }, 
                "name": "Suleyman Demirel University"
            }, 
            "investigator": [
                {
                    "last_name": "Mehmet Ozaydin, Proffesor,MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "\u0130brahim Ersoy, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of N-acetyl Cysteine on Major Cardiac and Cerebral Events in Patients Undergoing Primary Percutaneous Coronary Intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Major cardiac and cerebral events", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878344"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Suleyman Demirel University", 
            "investigator_full_name": "Mehmet Ozaydin, MD", 
            "investigator_title": "MD, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "NAC side effects (Asthma exacerbation, Pruritus, Dyspnea)", 
            "safety_issue": "Yes", 
            "time_frame": "during hospitalization at 48 hours"
        }, 
        "source": "Suleyman Demirel University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Suleyman Demirel University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}